Jason E. Tester

TARS

DIRECTOR · TARSUS PHARMACEUTICALS, INC. · CIK 0001827272

FILING MIX · LIFETIME62%/38%

BUYS

SELLS

TOTAL VALUE

$2.75M

COMPANIES

ACTIVE SINCE

Oct 2020

HOLDINGS NOW

10,000

AVG SELL PX

—

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

2 backtested trades · 8 horizonsHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Jason E. Tester, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	2	+0.00%	-4.79%	-1.50%	-3.28%	-3.28%	—
14d	2	+100.00%	+10.61%	-2.14%	+12.75%	+12.75%	—
30d	2	+100.00%	+10.32%	+4.20%	+6.13%	+6.13%	—
60d	2	+100.00%	+133.95%	+7.97%	+125.97%	+125.97%	—
90d	2	+100.00%	+99.67%	+10.74%	+88.93%	+88.93%	—
180d	2	+100.00%	+31.26%	+21.83%	+9.43%	+9.43%	—
1y	2	+100.00%	+33.99%	+33.61%	+0.38%	+0.38%	—
2y	2	+0.00%	-25.32%	+9.55%	-34.87%	-34.87%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

TARS · 10,000 shares · as of Jun 15, 2021

Trading cadence · quarterly flow

BUY ● SELL ●

2020

2021

FLOW · 8 buys / 5 sellsCOVERAGE · 3 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASEGRANT Stock grant	10,000	—	—	10,000	Jun 15, 2021	Jun 17, 2021 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	21,575	—	—	21,575	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	SALE	21,575	—	—	0	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	SALE	1,434,790	—	—	0	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	SALE	3,698	—	—	0	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	245,966	—	—	1,680,756	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	1,434,790	—	—	1,434,790	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	SALE	71,427	—	—	0	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	168,750	$16.00	$2.70M	1,920,933	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	3,125	$16.00	$50.0K	28,398	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	3,698	—	—	25,273	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	SALE	245,966	—	—	0	Oct 20, 2020	Oct 20, 2020 ↗	View →
TARS TARSUS PHARMACEUTICALS, INC.	PURCHASE	71,427	—	—	1,752,183	Oct 20, 2020	Oct 20, 2020 ↗	View →

Other insiders · TARS

Loading peer insiders…

About this filer

CIK 0001827272

ROLE

Director

PRIMARY

TARS

COMPANIES

ACTIVE SINCE

Oct 2020

MARKETPEEL · /INSIDER/0001827272DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Jason E. Tester

The morning brief, before the bell.